Vimarsana
Biggest News Aggregation in the World

Page 2 - Equal Life News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equal Life. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equal Life Today - Breaking & Trending Today

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant) - Vimarsana News

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human...

Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society - Vimarsana News

Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new pooled efficacy and safety analyses from the...

Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause - Vimarsana News

Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3b...

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause - Vimarsana News

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause - Vimarsana News

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

 VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. today... | June 14, 2023